Objective: To assess the right-to-left and short-term variability of intraepidermal nerve fiber density (IENFD) at the distal site of the leg.
Intraepidermal nerve fiber density (IENFD) at the distal site of the leg is a widely used tool to confirm the diagnosis of small fiber neuropathy (SFN). 1 The availability of age-and sex-adjusted reference values has improved the reliability of the method based on bright-field immunohistochemistry. 2 Skin biopsy, like electrodiagnostic studies, is usually performed unilaterally, and no recommendation currently exists to perform it on the right or left side for diagnosing SFN. However, while the right-to-left concordance of sural nerve conduction velocity and amplitude has been investigated in patients with neuropathy and healthy volunteers (HVs), 3 it is unknown whether this variable can affect the diagnostic performance of skin biopsy. One further variable is the consistency of IENFD over a short period of time. Skin is a self-renewal tissue, and the epidermis has an active turnover estimated at about 40 days. 4 The loss of IENF, which is the hallmark of SFN, can modify the architecture of the epidermis and possibly of keratinocyte functioning, which are part of the complex peripheral network involved in thermal sensation and nociception. 5 It is unknown whether epidermis turnover can influence IENFD in neuropathy and HVs. Our study aimed at addressing the right-to-left and time variability of IENFD over a period of 20 days, namely, the estimated half-life for the complete epidermis renewal, in patients with SFN and HVs. Our results strengthen the robustness of skin biopsy in diagnosing SFN and support its use as a biomarker in clinical trials.
METHODS Consecutive patients referred for a skin biopsy to confirm the diagnosis of possible or probable symmetric SFN according to published criteria 6 were enrolled. All patients underwent a thorough screening for known causes of SFN. HVs recruited among hospital employers and patients' relatives were asked to participate. Inclusion criteria for HVs were no symptoms or risk factors for neuropathy and a normal neurologic examination. Exclusion criteria for both groups were anticoagulant treatment, known bleeding disorders, and local skin infections. All participants underwent skin biopsies at the right and left distal leg, 10 cm above the external malleolus within the territory of the sural nerve. A subgroup of participants was asked to undergo follow-up biopsies 20 days later 2 to 3 mm apart from the scar of the prior biopsy. All biopsies were taken using a disposable 3-mm punch, under sterile technique, and after topical anesthesia with spray ice. No suture was needed.
The immunostaining procedure was performed following published guidelines using polyclonal anti-protein gene product 9.5 antibodies (UltraClone Ltd., Isle of Wight, UK). 1 Briefly, specimens were fixed (2% paraformaldehydelysine-sodium periodate, 4°C overnight), cryoprotected, and serially cut with a cryostat. Each 3-mm punch biopsy yielded about 45 vertical 50-mm sections. To decrease the variability of section length, IENFD was quantified on 3 nonconsecutive central sections (e.g., no. 25, 27, 29). All fibers crossing the dermal-epidermal junction, excluding fragments and secondary branching, were counted and their number was divided by the length of the epidermis to obtain a linear density (IENF/mm). Counts were performed by 2 expert operators blinded to conditions (diagnosis, side, and time of biopsy). IENFD was compared with sex-and age-adjusted normative values. 2 7 In patients with SFN, mean and median IENFD values were 2.45 IENF/mm and 2.3 IENF/mm 6 1.45 SD at the right side, and 2.4 IENF/mm and 2.2 IENF/mm 6 1.32 SD at the left side, a nonsignificant difference. In 35 of 40 patients, IENFD was bilaterally below the fifth percentile. Among the remaining patients, only 2 (no. 15 and 18; idiopathic SFN) had IENFD bilaterally about 30% higher than the cutoff, thus not confirming the diagnosis of SFN pathologically, whereas the others (no. 4, 9, 10) showed values at the cutoff, making the diagnosis possible pathologically. In HVs, mean and median values of IENFD were 6.38 IENF/mm and 6.3 IENF/mm 6 2.81 SD at the right side, and 6.0 IENF/mm and 6.2 IENF/mm 6 2.3 SD at the left side, a nonsignificant difference. In 15 of 17 HVs, IENFD was bilaterally above the fifth percentile. Of the remaining 2 HVs, one (no. 54) had IENFD about 10% lower than the cutoff, whereas the other (no. 53) had IENFD at the cutoff (table e-1). The right-to-left correlation of IENFD computed for all participants was excellent ( figure) . The correlation analysis between IENFD at baseline and 20-day follow-up was performed in 15 patients with SFN and 8 HVs (table 1) . Mean and median values did not differ between sides and the linear regression analysis yielded an excellent correlation (figure). DISCUSSION Skin biopsy performed using a 3-mm disposable punch is safe and minimally invasive, with minor side effects in ,2/1,000 individuals. 1 It can be easily repeated in the same area for follow-up studies because of the lack of IENFD variability between counts obtained from close biopsies in the same sensory nerve territory. 8 However, the variability of IENFD between the right and left distal leg and within a 20-day frame, which is the half-time of epidermis renewal, has not been investigated to date. We demonstrate that the value of IENFD is independent of the side where biopsy is performed and, likely, epidermis turnover. If IENFD was affected by the turnover of keratinocytes, a follow-up biopsy at their half-life of renewal should have captured any related change. In the absence of any factor that can vary IENFD, such as neuropathy progression, biopsy in a different sensory nerve territory, technical issues in biopsy processing section, and number of sections quantified, 9 any significant change would be attributed to intrinsic skin variables. Since we used the bright-field method and not indirect immunofluorescence, 10 we did not reassess intra-and interobserver agreement on IENFD quantification, knowing its excellent results have already been published. 1 Our results, showing overlapping values and excellent correlation coefficients for IENFD quantification both in HVs and patients with SFN, confirmed that skin biopsy can be performed unilaterally to assess the diagnosis of SFN in individual patients and that IENFD can be reliably used as a biomarker of small nerve fiber degeneration within a 3-week period. These findings can strengthen the use of skin biopsy also as outcome measure in clinical trials.
